HMGN (Hemagen Diagnostics) Market Cap: $0.00 Mil (As of Sep. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Hemagen Diagnostics Market Cap?

Hemagen Diagnostics HMGN Market Cap is $0.00 Mil as of Sep. 01, 2026.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Hemagen Diagnostics's share price for the quarter that ended in Sep. 2012 was $0.035. Hemagen Diagnostics's Shares Outstanding (EOP) for the quarter that ended in Sep. 2012 was 15.60 Mil. Therefore, Hemagen Diagnostics's market cap for the quarter that ended in Sep. 2012 was $0.55 Mil.

Hemagen Diagnostics's quarterly market cap increased from Mar. 2012 ($0.47 Mil) to Jun. 2012 ($0.62 Mil) but then declined from Jun. 2012 ($0.62 Mil) to Sep. 2012 ($0.55 Mil).

Hemagen Diagnostics's annual market cap declined from Sep. 2010 ($0.93 Mil) to Sep. 2011 ($0.47 Mil) but then increased from Sep. 2011 ($0.47 Mil) to Sep. 2012 ($0.55 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Hemagen Diagnostics's Enterprise Value for Today is $0.00 Mil.


Hemagen Diagnostics  (OTCPK:HMGN) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Hemagen Diagnostics Market Cap Related Terms


Hemagen Diagnostics Market Cap Historical Data

* Premium members only.

The historical data trend for Hemagen Diagnostics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemagen Diagnostics Market Cap Chart

Hemagen Diagnostics Annual Data
Trend Sep03 Sep04 Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.83 1.22 0.93 0.47 0.55

Hemagen Diagnostics Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.33 0.47 0.62 0.55

HMGN vs OBMP, NSPX, ATRX: Market Cap Comparison

For the Biotechnology subindustry, Hemagen Diagnostics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemagen Diagnostics Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemagen Diagnostics's Market Cap distribution charts can be found below:

* The bar in red indicates where Hemagen Diagnostics's Market Cap falls into.



Hemagen Diagnostics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Hemagen Diagnostics's Market Cap for the fiscal year that ended in Sep. 2012 is calculated as

Market Cap (A: Sep. 2012 )=Share Price (A: Sep. 2012 )*Shares Outstanding (EOP) (A: Sep. 2012 )
=$0.035*15.600
=$0.55

Hemagen Diagnostics's Market Cap for the quarter that ended in Sep. 2012 is calculated as

Market Cap (Q: Sep. 2012 )=Share Price (Q: Sep. 2012 )*Shares Outstanding (EOP) (Q: Sep. 2012 )
=$0.035*15.600
=$0.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of $0.00 Mil mean?
Hemagen Diagnostics (HMGN) has a Market Cap of $0.00 Mil as of Sep. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Hemagen Diagnostics and its competitors.
Is Hemagen Diagnostics' Market Cap too high?
Hemagen Diagnostics' current Market Cap is $0.00 Mil.
How does Hemagen Diagnostics' Market Cap compare to OBMP and NSPX?
Hemagen Diagnostics' Market Cap of $0.00 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 121.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.77, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Hemagen Diagnostics and its competitors. For the Biotechnology industry, the median Market Cap is 121.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hemagen Diagnostics's current Market Cap is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemagen Diagnostics stock overvalued right now?
Hemagen Diagnostics (HMGN) has a current Market Cap of $0.00 Mil. The current Market Cap is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Hemagen Diagnostics (HMGN), the current Market Cap is $0.00 Mil as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemagen Diagnostics Business Description

Address 9033 Red Branch Road, Columbia, MD, USA, 21045
Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.